The ONE InstantCare: COVID-19 antibodies ultramicro-quantitative rapid test platform

The ONE InstantCare:
COVID-19 antibodies ultramicro-quantitative rapid test platform
SpectroChip Inc.

Nowadays, COVID-19 rapid tests are conducted in a physical and qualitative way. However, SpetroChip's product, The ONE InstantCare, can quantitatively analyze The antibodies rapid tests with its "spectrochip" technology. It is The only important technology in the world that can achieve micro and quantitative antibodies rapid tests for COVID-19.From the sample to the test result can be completed within 15 minutes, and the data will be uploaded to the cloud database. This breakthrough technology will play an important role in COVID-19 prevention and is highly valued by the US FDA. SpetroChip Inc. is also actively integrating and developing antigen rapid tests, which will become a more comprehensive rapid tests platform for COVID-19.

Epidemic Prevention Advantage：
1. Solving the problem of false negative coVID-19 rapid tests.
2. Improving the clinical application of COVID-19 rapid tests.
3. Expanding the screening energy of coVID-19 rapid tests.
4. Constructing a COVID-19 rapid tests protection system.

Collaboration Options：Marketing and promotion, clinical research cooperation, investment

Contact Person：Andy Tsai
Mobile Phone：+886-919-612600
Email Address：[email protected]